Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Taiwan · Delayed Price · Currency is TWD

31.90

+0.05 (0.16%)

Jun 18, 2026, 1:30 PM CST

2.90% (1Y)

Market Cap	6.07B +0.4%
Revenue (ttm)	3.39B +6.7%
Net Income	327.17M +6.7%
EPS	1.72 +6.9%
Shares Out	190.20M
PE Ratio	18.54
Forward PE	n/a
Dividend	1.00 (3.13%)
Ex-Dividend Date	Jul 24, 2026

Volume	387,131
Open	31.90
Previous Close	31.85
Day's Range	31.65 - 31.95
52-Week Range	29.62 - 32.60
Beta	0.12
Analysts	Hold
Price Target	29.52 (-7.46%)
Earnings Date	Aug 12, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1977

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1734

Full Company Profile

Financial Performance

In 2025, Sinphar Pharmaceutical's revenue was 3.37 billion, an increase of 7.00% compared to the previous year's 3.15 billion. Earnings were 365.75 million, an increase of 20.03%.

Financial Statements